Topicaal ingenol mebutaat versus 5% 5-fluorouracil versus 5% imiquimod versus fotodynamische therapie als behandeling van actinische keratosen: Een multicenter gerandomiseerde kosten effectiviteitsstudie: het protocol van de AKTI-studie

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

To date, there is no consensus on the treatment of actinic
keratosis (AK). Current national and international guidelines
state no clear recommendations for the best choice
of therapy. To determine the most effective treatment in
terms of lesion reduction, costs and patient satisfaction
topical treatment with 0.015% ingenol mebutate gel, 5%
5-fluorouracil cream, 5% imiquimod cream and photodynamic
therapy were compared in a prospective randomized
controlled multi-centre study. Patients older than 18
years with a Fitzpatrick skintype I-IV, with 5 AK’s Olsen
class I-III in an area of minimal 25 cm2
and maximal 100
cm2
, localized in the head and neck area were included in
the study. In total 624 were included in the Dermatology
departments of the Maastricht University Medical
Centre, Catharina hospital Eindhoven, Zuyderland
Medical Centre Heerlen and VieCuri Medical Centre
Venlo/Venray. Primary outcome measure is treatment
success, defined as the proportion of participants with
≥ 75% reduction of the number of AK lesions in the
treatment area at 12 months post final treatment compared
to baseline. Secondary outcome is treatment success
at 3 months post final treatment, cost-effectiveness, side
effects, patient satisfaction, cosmetic outcome and treatment
compliance.
Original languageDutch
Pages (from-to)554-556
Number of pages3
JournalNederlands Tijdschrift voor Dermatologie en Venereologie
Volume27
Issue number10
Publication statusPublished - Oct 2017

Cite this

@article{b45a605413954b44a609faf22b9097fb,
title = "Topicaal ingenol mebutaat versus 5{\%} 5-fluorouracil versus 5{\%} imiquimod versus fotodynamische therapie als behandeling van actinische keratosen: Een multicenter gerandomiseerde kosten effectiviteitsstudie: het protocol van de AKTI-studie",
abstract = "To date, there is no consensus on the treatment of actinickeratosis (AK). Current national and international guidelinesstate no clear recommendations for the best choiceof therapy. To determine the most effective treatment interms of lesion reduction, costs and patient satisfactiontopical treatment with 0.015{\%} ingenol mebutate gel, 5{\%}5-fluorouracil cream, 5{\%} imiquimod cream and photodynamictherapy were compared in a prospective randomizedcontrolled multi-centre study. Patients older than 18years with a Fitzpatrick skintype I-IV, with 5 AK’s Olsenclass I-III in an area of minimal 25 cm2 and maximal 100cm2, localized in the head and neck area were included inthe study. In total 624 were included in the Dermatologydepartments of the Maastricht University MedicalCentre, Catharina hospital Eindhoven, ZuyderlandMedical Centre Heerlen and VieCuri Medical CentreVenlo/Venray. Primary outcome measure is treatmentsuccess, defined as the proportion of participants with≥ 75{\%} reduction of the number of AK lesions in thetreatment area at 12 months post final treatment comparedto baseline. Secondary outcome is treatment successat 3 months post final treatment, cost-effectiveness, sideeffects, patient satisfaction, cosmetic outcome and treatmentcompliance.",
author = "M.H.E. Jansen and J.P.H.M. Kessels and P.J. Nelemans and B.A. Essers and {Kelleners - Smeets}, N.W.J. and K. Mosterd",
year = "2017",
month = "10",
language = "Dutch",
volume = "27",
pages = "554--556",
journal = "Nederlands Tijdschrift voor Dermatologie en Venereologie",
issn = "0925-8604",
publisher = "DCHG Partners in Mediscne Communicatie",
number = "10",

}

TY - JOUR

T1 - Topicaal ingenol mebutaat versus 5% 5-fluorouracil versus 5% imiquimod versus fotodynamische therapie als behandeling van actinische keratosen

T2 - Een multicenter gerandomiseerde kosten effectiviteitsstudie: het protocol van de AKTI-studie

AU - Jansen, M.H.E.

AU - Kessels, J.P.H.M.

AU - Nelemans, P.J.

AU - Essers, B.A.

AU - Kelleners - Smeets, N.W.J.

AU - Mosterd, K.

PY - 2017/10

Y1 - 2017/10

N2 - To date, there is no consensus on the treatment of actinickeratosis (AK). Current national and international guidelinesstate no clear recommendations for the best choiceof therapy. To determine the most effective treatment interms of lesion reduction, costs and patient satisfactiontopical treatment with 0.015% ingenol mebutate gel, 5%5-fluorouracil cream, 5% imiquimod cream and photodynamictherapy were compared in a prospective randomizedcontrolled multi-centre study. Patients older than 18years with a Fitzpatrick skintype I-IV, with 5 AK’s Olsenclass I-III in an area of minimal 25 cm2 and maximal 100cm2, localized in the head and neck area were included inthe study. In total 624 were included in the Dermatologydepartments of the Maastricht University MedicalCentre, Catharina hospital Eindhoven, ZuyderlandMedical Centre Heerlen and VieCuri Medical CentreVenlo/Venray. Primary outcome measure is treatmentsuccess, defined as the proportion of participants with≥ 75% reduction of the number of AK lesions in thetreatment area at 12 months post final treatment comparedto baseline. Secondary outcome is treatment successat 3 months post final treatment, cost-effectiveness, sideeffects, patient satisfaction, cosmetic outcome and treatmentcompliance.

AB - To date, there is no consensus on the treatment of actinickeratosis (AK). Current national and international guidelinesstate no clear recommendations for the best choiceof therapy. To determine the most effective treatment interms of lesion reduction, costs and patient satisfactiontopical treatment with 0.015% ingenol mebutate gel, 5%5-fluorouracil cream, 5% imiquimod cream and photodynamictherapy were compared in a prospective randomizedcontrolled multi-centre study. Patients older than 18years with a Fitzpatrick skintype I-IV, with 5 AK’s Olsenclass I-III in an area of minimal 25 cm2 and maximal 100cm2, localized in the head and neck area were included inthe study. In total 624 were included in the Dermatologydepartments of the Maastricht University MedicalCentre, Catharina hospital Eindhoven, ZuyderlandMedical Centre Heerlen and VieCuri Medical CentreVenlo/Venray. Primary outcome measure is treatmentsuccess, defined as the proportion of participants with≥ 75% reduction of the number of AK lesions in thetreatment area at 12 months post final treatment comparedto baseline. Secondary outcome is treatment successat 3 months post final treatment, cost-effectiveness, sideeffects, patient satisfaction, cosmetic outcome and treatmentcompliance.

M3 - Article

VL - 27

SP - 554

EP - 556

JO - Nederlands Tijdschrift voor Dermatologie en Venereologie

JF - Nederlands Tijdschrift voor Dermatologie en Venereologie

SN - 0925-8604

IS - 10

ER -